India, US Deepen Ties in Advanced Biomanufacturing

• Jitendra Singh called for structured India–US ties in advanced biomanufacturing to boost global competitiveness
• Proposal includes co-developing affordable biologics, biosimilars, and vaccines
• Both sides agreed to form a working group to drive joint research, startup exchanges

India aims to establish a partnership with the United States through advanced biomanufacturing, according to Science and Technology Minister Jitendra Singh, who demands a more organized method to develop joint operations which will improve their international market competitiveness.

The India US biomanufacturing partnership marks a significant step in strengthening advanced biomanufacturing cooperation, as highlighted in the Jitendra Singh statement, reinforcing India US strategic ties, expanding biotech collaboration India US, deepening the life sciences partnership, and advancing innovation in industrial biotechnology.

Advanced biomanufacturing uses living systems together with modern technologies to create medicines, vaccines, biologics and sustainable fuels.

Singh established science technology and biotechnology as the essential elements which define the India-US comprehensive strategic partnership during his discussion with the US delegation, which Matt Meyer led.

Also Read: India Joins U.S.-led Pax Silica Strategic Tech Coalition

He proposed international scientific research through the development of affordable biologics, biosimilars and vaccines, which would support health needs worldwide. The partnership could combine India's affordable production capabilities with Delaware's access to major US pharmaceutical manufacturers, according to him.

The minister also emphasized expanding research partnerships between Indian institutions and Delaware-based research centers, developing startup and incubation connections between both entities, and creating workforce training programs which will teach Good Manufacturing Practices, regulatory science and quality systems.

The two parties established regulatory alignment and standards harmonization and critical biopharmaceutical supply chain development as their main focus areas.

Singh explained that the Centre's research and development and innovation fund, worth Rs 1 lakh crore, will enable Delaware's research and startup ecosystem to deepen its connections with the Centre. The two parties established a structured working group system, which will transform their discussions into actual programs.